放射治疗ⅠE期非结膜眼附属器黏膜相关淋巴组织型淋巴瘤的剂量效应和预后

赵水喜; 俞立权; 布洁; 曹京旭; 肖利华

PDF(591 KB)

武警医学 ›› 2016, Vol. 27 ›› Issue (12) : 1249-1252.

论著

放射治疗ⅠE期非结膜眼附属器黏膜相关淋巴组织型淋巴瘤的剂量效应和预后

赵水喜¹, 俞立权¹, 布洁¹, 曹京旭¹, 肖利华²

作者信息 +

Non-conjunctival primary ocular adnexal mucosa associated lymphoid tissue lymphoma(POAML) treated with primary radiotherapy

ZHAO Shuixi¹, YU Liquan¹, BU Jie¹, CAO Jingxu¹, and XIAO Lihua²

Author information +

文章历史 +

摘要

目的评价放射治疗ⅠE期非结膜原发眼附属器黏膜相关淋巴组织型淋巴瘤的剂量效应和预后。方法回顾性分析2003-11至2012-03收治的影像资料完整可测量33例(42只眼)ⅠE期非结膜原发眼附属器黏膜相关淋巴组织型淋巴瘤患者资料。结果照射剂量18 Gy时与27 Gy时,依据WHO标准评价疗效,缓解率分别为31%和42.9%(P=0.258);依据RECIST标准评价疗效,缓解率分别为28.6和38.1%(P=0.355)。全组患者局部控制率100%。全组患者的5年、10年总生存(OS)率分别为96.8%和84.7%; 5、10年无进展生存(PFS)率分别为89.6%和89.6%。接受≥30.6Gy组与27 Gy组,5、10年总生存(OS)率分别为100%、80%和95.7%、95.7%(P=0.8578); 5、10年无进展生存(PFS)生存率分别为83.3%、83.3%和91.1%、91.1%(P=0.6497)。结论非结膜原发眼附属器黏膜相关淋巴组织型淋巴瘤对放射治疗敏感。从局部控制和长期生存的观察结果显示,27 Gy的照射剂量是足够的。探索最佳的照射剂量需要开展前瞻性大样本的剂量效应观察研究。

Abstract

Objective To evaluate the dose response of patients with ⅠE stage non-conjunctival primary ocular adnexal mucosa associated lymphoid tissue lymphoma(POAML) treated with primary radiotherapy.Methods Clinical data on thirty-three patients(42 eyes) with stage Ⅰnon-conjunctival POAML treated between November 2003 and Match 2012 were retrospectively studied.Results For all the patients, the local control rate was 100% at the dose of 18 Gy and 27 Gy, while the response rate was 31% and42.9%(P=0.258)respectively as measured with the WHO criteria. However, the response rate was 28.6% and38.1%(P=0.355)respectively as measured with the RECIST criteria. For patients of non-conjunctival POAML treated at the dose of ≥30.6 Gy and 27 Gy, the five-year overall survival(OS) rate was 100% and 95.7% respectively (P=0.8578), and the five-year progression-free survival(PFS) rate was 83.3% and 91.1% respectively (P=0.6497).Conclusions The prescribed dose of 27 Gy for non-conjunctival POAML seems to be effective. Prospective clinical studies should be carried out to define the optimal dose for POAML.

导出引用

赵水喜, 俞立权, 布洁, 曹京旭, 肖利华. 放射治疗ⅠE期非结膜眼附属器黏膜相关淋巴组织型淋巴瘤的剂量效应和预后[J]. 武警医学. 2016, 27(12): 1249-1252

ZHAO Shuixi, YU Liquan, BU Jie, CAO Jingxu, and XIAO Lihua. Non-conjunctival primary ocular adnexal mucosa associated lymphoid tissue lymphoma(POAML) treated with primary radiotherapy[J]. Medical Journal of the Chinese People Armed Police Forces. 2016, 27(12): 1249-1252

中图分类号： R733

参考文献

[1] Lazzarino M, Morra E, Rosso R, et al. Clinicopathologic and immunologic characteristics of non Hodgkin’s lymphoma presenting in the orbit[J]. Cancer,1985,55(9):1907-1912.
[2] Bairey O, Kremer I, Rakowsky E, et al. Orbital and adnexal involvement in systemic non-Hodgkin’s lymphoma[J]. Cancer,1994,73(9):2395-2399.
[3] Freeman C, Berg J W, Cutler S J. Occurrence and prognosis of extranodal lymphomas[J]. Cancer,1972,29(1):252-260.
[4] White W L,Ferry J A,Harris N L,et al.Ocular adnexal lymphoma: a clinicopathologic study with identi cation of lymphomas of mucosa-associated lymphoid tissue type[J].Ophthalmology,1995,102(12):1994-2006.
[5] McKelvie P A, McNab A, Francis I C, et al. Ocular adnexal lymphoproliferative disease: a series of 73 cases[J].Clin Experiment Ophthalmol,2001,29(6):387-393.
[6] Meunier J, Lumbroso-Le Rouic L, et al. Ophthalmologic and intraocular non-Hodgkin’s lymphoma: a large single centre study of initial characteristics, natural history, and prognostic factors[J]. Hematol Oncol,2004,22(4):143-158.
[7] Ferry J A, Fung C Y, Zukerberg L, et al. Lymphoma of the ocular adnexa: a study of 353 cases[J]. Am J Surg Pathol,2007,31(2):170-184.
[8] Nakata M, Matsuno Y, Katsumata N, et al. Histology according to the Revised European-American Lymphoma Classification significantly predicts the prognosis of ocular adnexal lymphoma[J]. Leuk Lymphoma,1999,32(5-6):533-543.
[9] Mannami T,Yoshino T, Oshima K, et al. Clinical, histopathological, and immunogenetic analysis of ocular adnexal lymphoproliferative disorders: characterization of MALT lymphoma and reactive lymphoid hyperplasia[J]. Mod Pathol,2001,14(7):641-649.
[10] Cho E Y, Han J J, Ree H J, et al. Clinicopathologic analysis of ocular adnexal lymphomas: extranodal marginal zone B-cell lymphoma constitutes the vast majority of ocular lymphomas among Koreans and affects younger patients[J]. Am J Hematol,2003,73(2):87-96.
[11] Lee J L, Kim M K, Lee K H, et al. Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue type of the orbit and ocular adnexa[J]. Ann Hematol, 2005,84(1):13-18.
[12] Woo J M, Tang C K, Rho M S, et al. The clinical characteristics and treatment results of ocular adnexal lymphoma[J]. Korean J Ophthalmol,2006,20(1):7-12.
[13] Yoon J S,Ma K T,Kim S J,et al.Prognosis for patients in a Korean population with ocular adnexal lymphoproliferative lesions[J].Ophthal Plast Reconstr Surg,2007,23(2):94-99.
[14] Le Q T, Eulau S M, George T I, et al. Primary radiotherapy for localized orbital MALT lymphoma[J]. Int J Radiat Oncol Biol Phys,2002,52(3): 657-663.
[15] Tsang R W, Gospodarowicz M K, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome[J]. J Clin Oncol,2003,21(22):4157-4164.
[16] Fung C Y, Tarbell N J, Lucarelli M J, et al. Ocular adnexal lymphoma: clinical behavior of distinct world health organization classification subtypes[J]. Int J Radiat Oncol Biol Phys,2003,57(5): 1382-1391.
[17] Hasegawa M, Kojima M, Shioya M, et al. Treatment results of radiotherapy for malignant lymphoma of the orbit and histopathological review according to the WHO classification[J]. Int J Radiat Oncol Biol Phys,2003,57(1):172-176.
[18] Uno T, Isobe K, Shikama N, et al. Radiotherapy for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa. A multiinstitutional, retrospective review of 50 patients[J]. Cancer,2003,98(4):865-871.
[19] Lee J L, Kim M K, Lee K H, et al. Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue-type of the orbit and ocular adnexa[J]. Ann Hematol,2005,84(1):13-18.
[20] Aviles A, Neri N, Calva A, et al. Addition of a short course of chemotherapy did not improve outcome in patients with localized marginal B-cell lymphoma of the orbit[J]. Oncology,2006,70(3):173-176.
[21] Suh C O, Shim S J, Lee S W, et al. Orbital marginal zone B-cell lymphoma of MALT: radiotherapy results and clinical behavior[J]. Int J Radiat Oncol Biol Phys, 2006,65(1):228-233.
[22] Ejima Y,Sasaki R,Okamoto Y,et al.Ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy[J].Radiother Oncol,2006,78(1):6-9.
[23] Yamashita H,Nakagawa K,Asari T,et al.Radiotherapy for 41 patients with stages I and II MALT lymphoma: a retrospective study[J].Radiother Oncol,2008,87(3):412-417.
[24] Nam H,Ahn Y C,Kim Y D,et al.Prognostic significance of anatomic subsites:results of radiation therapy for 66 patients with localized orbital marginal zone B cell lymphoma[J].Radiother Oncol,2009,90(2):236-241.
[25] Son S H, Choi B O, Kim G W, et al. Primary radiation therapy in patients with localized orbital marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) [J]. Int J Radiat Oncol Biol Phys,2010,77(1):86-91.
[26] Hata M, Omura M, Koike I, et al. Treatment effects and sequelae of radiation therapy for orbital mucosa-associated lymphoid tissue lymphoma[J]. Int J Radiat Oncol Biol Phys, 2011,81(5):1387-1393.
[27] Goda J S, Le L W, Lapperriere N J, et al. Localized orbital mucosa-associated lymphoma tissue lymphoma managed with primary radiation therapy: efficacy and toxicity[J]. Int J Radiat Oncol Biol Phys,2011,81(4):e659-666.
[28] Hashimoto N, Sasaki R, Nishimura H, et al. Long-term outcome and patterns of failure in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy[J]. Int J Radiat Oncol Biol Phys,2012,82(5): 1509-1514.
[29] Ohja S, Nakamura K, Shioyama Y, et al. Treatment outcome of radiotherapy for localized primary ocular adnexal MALT lymphoma-prognostic effect of the AJCC Tumor-Node-Metastasis clinical staging system[J].Anticancer Res,2015,35(6):3591-3597.
[30] Jung S K, Paik J S, Jung S E, et al. Suggestion of response evaluation criteria in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma (OAML) [J]. Ann Hematol,2015,94(7):1185-1193
[31] Gayed I, Eskandari M F, McLaughlin P, et al. Value of positron emission tomography in staging ocular adnexal lymphomas and evaluating their response to therapy[J]. Ophthalmic Surg Lasers Imaging,2007,38(4):319-325.
[32] Harada K, Murakami N, Kitaguchi M, et al. Localized ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiation therapy: a long-term outcome in 86 patients with 104 treated eyes[J]. Int J Radiat Oncol Biol Phys,2014,88(3):650-654.